Highlights

  • TruScreen CEO Martin Dillon has resigned for personal reasons, effective 31 October 2026.
  • Chairman Tony Ho will assume the responsibilities of Executive Chairman and Interim CEO during the transition.
  • The company will begin a recruitment process for a new permanent Chief Executive Officer.
  • Dillon will remain available as a consultant after his departure if additional transition support is required.

TruScreen Group Limited (ASX:TRU) is a medical device company that develops and manufactures AI-enabled technology for cervical cancer screening. Its TruScreen Ultra device is designed to detect abnormalities in cervical tissue in real time using optical and electrical measurements, without relying on conventional biological tissue sampling and laboratory processing. The company has now entered a Leadership transition period following the resignation of Chief Executive Officer Martin Dillon, with existing chairman Tony Ho stepping into an interim executive role.

Martin Dillon to Leave CEO Role at End of October

TruScreen advised that Martin Dillon has resigned as Chief Executive Officer for personal reasons, with his departure taking effect from 31 October 2026.

The company has not announced a permanent replacement at this stage. Instead, Non-Executive Independent Chairman Tony Ho will assume the responsibilities of Executive Chairman and Interim CEO while the board undertakes a recruitment process for a new chief executive.

The board stated that TruScreen’s existing executive team is expected to continue managing operations and strategic priorities during the transition. Dillon will also remain available to the company in a consulting capacity after his formal departure if support is required.

Interim Leadership Provides Operational Continuity

Tony Ho’s assumption of the interim CEO role means the leadership transition will initially be managed internally rather than through an immediate external appointment.

This arrangement provides continuity between the board and management while recruitment is undertaken. The announcement does not provide a timetable for appointing a permanent CEO, nor does it disclose whether internal or external candidates are being considered.

For market observers, the main operational issue is therefore continuity during the search process. TruScreen has indicated that the existing executive team will continue to oversee the company’s operations and strategic priorities, limiting immediate structural changes while leadership responsibilities are reassigned.

Recent Market Expansion Formed Part of Dillon’s Tenure

In commenting on Dillon’s departure, TruScreen highlighted market development activity undertaken during his tenure, particularly over the past year.

The company referenced the opening of new markets across Central Asia, Indonesia, India, Malaysia, Thailand and greater Africa. These geographic additions indicate that international commercial expansion has been an important part of TruScreen’s recent operating strategy.

However, the announcement does not provide new sales figures, Revenue guidance or device-volume forecasts associated with these markets. As a result, the leadership announcement should be viewed primarily as a management transition update rather than a financial or trading update.

The board said it would provide further information to the market as appropriate, leaving the timing of the permanent appointment as the key unresolved corporate development.

TruScreen Continues Focus on AI-Enabled Cervical Screening

TruScreen’s core Business is centred on cervical cancer screening technology. Its device measures optical and electrical responses in cervical tissue to identify abnormalities in real time.

The company states that its technology avoids biological tissue sampling and processing, which can reduce reliance on laboratory infrastructure and specialised personnel. The TruScreen Ultra device is registered as a primary cervical cancer screening device.

The product is registered or approved for clinical use across a number of international markets, and the company has distributors in 29 countries. This international footprint provides context for why leadership continuity matters as TruScreen continues managing commercial activity across multiple jurisdictions.

The company has also disclosed that more than 200 devices have been installed and used across several markets. Those figures provide a sense of the installed base supporting TruScreen’s broader commercial operations, although they are not updated financial measures for FY2026.

Key Takeaway

TruScreen Group Limited (ASX:TRU) is entering a leadership transition following Martin Dillon’s resignation as CEO. Tony Ho will take responsibility as Executive Chairman and Interim CEO while a permanent replacement is sought, with the existing management team continuing to oversee day-to-day operations and strategic priorities. The announcement does not contain new financial guidance or operating forecasts, making the progress of the CEO recruitment process the main corporate development to watch.